STAT3 rs4796793 contributes to lung cancer risk and clinical outcomes of platinum-based chemotherapy

  • Wei-Jing Gong
  • Li-Yun Ma
  • Lei Hu
  • Yong-Ning Lv
  • Hong Huang
  • Jia-Qiang Xu
  • Dan-Dan Huang
  • Rui-Jie Liu
  • Yong Han
  • Yu Zhang
  • Shao-Jun Shi
  • San-Lan WuEmail author



Signal transducer and activator of transcription (STAT) 3 plays a vital role in carcinogenesis and drug response. Platinum-based chemotherapy is the first-line treatment for lung cancer patients, especially those in advanced stages. In the present study, we investigated the association of STAT3 polymorphism rs4796793 with lung cancer susceptibility, platinum-based chemotherapy response, and toxicity.


A total of 498 lung cancer patients and 213 healthy controls were enrolled in the study. 467 of them received at least 2-cycle platinum-based chemotherapy. Unconditional logistical regression analysis was used to assess the associations.


STAT3 rs4769793 G allele carriers had an increased susceptibility of lung cancer [additive model: adjusted OR (95% CI) 1.376 (1.058–1.789), P = 0.017; recessive model: adjusted OR (95% CI) 1.734 (1.007–2.985), P = 0.047]. Rs4769793 was not significantly associated with platinum-based chemotherapy response in lung cancer patients. STAT3 rs4796793 was associated with an increased risk of severe overall toxicity [additive model: adjusted OR (95% CI) 1.410 (1.076–1.850), P = 0.013; dominant model: adjusted OR (95% CI) 1.638 (1.091–2.459), P = 0.017], especially hematological toxicity [additive model: adjusted OR (95% CI) 1.352 (1.001–1.826), P = 0.049].


STAT3 rs4796793 may be considered as a potential candidate biomarker for the prediction of susceptibility and prognosis in Chinese lung cancer patients. However, well-designed studies with larger sample sizes are required to verify the results.


STAT3 rs4769793 Lung cancer Susceptibility Platinum-based chemotherapy Prognosis 



The authors thank all the subjects who volunteered to take part in the study.


The work was supported by the National Key R&D Program of China (No. 2017YFC0909900) and Hubei Province health and family planning scientific research project (WJ2017M118).

Compliance with ethical standards

Conflict of interest

All authors have no conflict of interest to disclose.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

10147_2018_1386_MOESM1_ESM.docx (10 kb)
Supplementary material 1 (DOCX 10 KB)
10147_2018_1386_MOESM2_ESM.jpg (816 kb)
Supplementary material 2 (JPG 816 KB)
10147_2018_1386_MOESM3_ESM.jpg (899 kb)
Supplementary material 3 (JPG 898 KB)
10147_2018_1386_MOESM4_ESM.docx (16 kb)
Supplementary material 4 (DOCX 15 KB)
10147_2018_1386_MOESM5_ESM.docx (15 kb)
Supplementary material 5 (DOCX 14 KB)


  1. 1.
    Chen W, Zheng R, Baade PD et al. (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132. CrossRefGoogle Scholar
  2. 2.
    Gong WJ, Yin JY, Li XP et al. (2016) Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response. Tumour Biol 37(6):8349–8358. CrossRefGoogle Scholar
  3. 3.
    Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9(11):798–809. CrossRefGoogle Scholar
  4. 4.
    Chai EZ, Shanmugam MK, Arfuso F et al. (2016) Targeting transcription factor STAT3 for cancer prevention and therapy. Pharmacol Ther 162:86–97. CrossRefGoogle Scholar
  5. 5.
    Yu H, Lee H, Herrmann A et al. (2014) Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 14(11):736–746. CrossRefGoogle Scholar
  6. 6.
    Lee HJ, Zhuang G, Cao Y et al. (2014) Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 26(2):207–221. CrossRefGoogle Scholar
  7. 7.
    Barre B, Vigneron A, Perkins N et al. (2007) The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med 13(1):4–11. CrossRefGoogle Scholar
  8. 8.
    Huang S, Chen M, Shen Y et al. (2012) Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Lett 315(2):198–205. CrossRefGoogle Scholar
  9. 9.
    Zhao L, Zhang Q, Luan X et al. (2015) STAT3 and STAT5b polymorphism contributes to breast cancer risk and clinical outcomes. Int J Clin Exp Pathol 8(2):2033–2038Google Scholar
  10. 10.
    Sonnenblick A, Uziely B, Nechushtan H et al. (2013) Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 138(2):407–413. CrossRefGoogle Scholar
  11. 11.
    Gong W, Xiao D, Ming G et al. (2014) Type 2 diabetes mellitus-related genetic polymorphisms in microRNAs and microRNA target sites. J Diabetes 6(4):279–289. CrossRefGoogle Scholar
  12. 12.
    Ito N, Eto M, Nakamura E et al. (2007) STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J Clin Oncol 25(19):2785–2791. CrossRefGoogle Scholar
  13. 13.
    Gong WJ, Peng JB, Yin JY et al. (2017) Association between well-characterized lung cancer lncRNA polymorphisms and platinum-based chemotherapy toxicity in Chinese patients with lung cancer. Acta Pharmacol Sin 38(4):581–590. CrossRefGoogle Scholar
  14. 14.
    Duffaud F, Therasse P (2000) New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer 87(12):881–886Google Scholar
  15. 15.
    Trotti A, Colevas AD, Setser A et al. (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176–181. CrossRefGoogle Scholar
  16. 16.
    Jiang B, Zhu ZZ, Liu F et al. (2011) STAT3 gene polymorphisms and susceptibility to non-small cell lung cancer. Genet Mol Res 10(3):1856–1865. CrossRefGoogle Scholar
  17. 17.
    Wang KN, Zhou B, Zhang J et al. (2011) Association of signal transducer and activator of transcription 3 gene polymorphisms with cervical cancer in chinese women. DNA Cell Biol 30(11):931–936. CrossRefGoogle Scholar
  18. 18.
    Xie J, Zhang Y, Zhang Q et al. (2013) Interaction of signal transducer and activator of transcription 3 polymorphisms with hepatitis B virus mutations in hepatocellular carcinoma. Hepatology 57(6):2369–2377. CrossRefGoogle Scholar
  19. 19.
    Zhao H, Wang Z, Wu H et al. (2015) STAT3 genetic variant, alone and in combination with STAT5b polymorphism, contributes to breast cancer risk and clinical outcomes. Med Oncol 32 (1).
  20. 20.
    Zhou F, Cheng L, Qiu LX et al. (2016) Associations of potentially functional variants in IL-6, JAKs and STAT3 with gastric cancer risk in an eastern Chinese population. Oncotarget 7(19):28112–28123. Google Scholar
  21. 21.
    Sellier H, Rebillard A, Guette C et al. (2013) How should we define STAT3 as an oncogene and as a potential target for therapy?. JAKSTAT 2 (3):e24716. Google Scholar
  22. 22.
    Walch-Ruckheim B, Pahne-Zeppenfeld J et al. (2016) STAT3/IRF1 pathway activation sensitizes cervical cancer cells to chemotherapeutic drugs. Cancer Res 76(13):3872–3883. CrossRefGoogle Scholar
  23. 23.
    Yamamoto K, Ioroi T, Kanaya K et al. (2016) STAT3 polymorphism rs4796793 may be a predictive factor of tumor response to multiple tyrosine kinase inhibitors in metastatic renal cell carcinoma in Japanese population. Med Oncol 33 (3):24. (Northwood, London, England)CrossRefGoogle Scholar
  24. 24.
    Jenkins BJ, Roberts AW, Greenhill CJ et al. (2007) Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis. Blood 109(6):2380–2388. CrossRefGoogle Scholar
  25. 25.
    Kirito K, Osawa M, Morita H et al. (2002) A functional role of Stat3 in in vivo megakaryopoiesis. Blood 99(9):3220–3227CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2019

Authors and Affiliations

  1. 1.Department of Pharmacy, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  2. 2.Department of PharmacyPeking University People’s HospitalBeijingChina
  3. 3.Wuhan Highway Management OfficeWuhanChina
  4. 4.Department of Nursing, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  5. 5.Department of Pathology, Xiangya HospitalCentral South UniversityChangshaChina

Personalised recommendations